Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment
A French real-world study, called AVENANCE, looked at avelumab maintenance treatment in people with advanced urothelial cancer whose tumor disappeared, shrank, or stopped growing with chemotherapy. Overall, results were consistent with those seen in a previous clinical trial, and on average, people treated with avelumab maintenance lived for 26.5 mo from the start of chemotherapy. Analyses of different groups of people found that survival varied, with people living for an average of 18-42 mo depending on what treatment they received after they finished avelumab treatment.
Authors
- Aude Fléchon (ORCID: https://orcid.org/0000-0002-0129-6101)
- Éric Voog (ORCID: https://orcid.org/0000-0001-8366-8003)
- Sylvestre Le Moulec (ORCID: https://orcid.org/0000-0003-4189-0890)
- Constant Josse (ORCID: https://orcid.org/0000-0002-8729-2397)
- Anne Escande
- Marie-Noelle Solbes
- M. Gross-Goupil
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Philippe Barthélémy (ORCID: https://orcid.org/0000-0003-3917-0579)
- Constance Thibault (ORCID: https://orcid.org/0000-0002-9082-1341)
- Prisca Lambert
- Véronique Lorgis
- Aurélien Gobert
- Matthieu Chasseray
- Camille Simon
- Damien Pouessel (ORCID: https://orcid.org/0000-0003-4030-8299)
- Guillaume Mouillet (ORCID: https://orcid.org/0000-0002-2288-7461)
- Werner Hilgers (ORCID: https://orcid.org/0000-0002-9828-6224)
- Emanuel Nicolas
- Jean‐Christophe Eymard
- Christine L. Abraham
Institutions
- Université Paris Cité (FR)
- Merck Serono S.A.S. (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut de Cancérologie de Lorraine (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centre Léon Bérard (FR)
- Bordeaux Population Health (FR)
- Institut de Cancérologie de Bourgogne (FR)
- Pfizer (France) (FR)
- Centre Hospitalier privé Saint Grégoire (FR)
- Clinique Victor Hugo (FR)
- Institut Jean Godinot (FR)
- Université de Nîmes (FR)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1016/j.euo.2024.09.014
- Citations
- 27
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 15.46
Funders
- Pfizer
- Merck
- Merck KGaA